Demographic characteristics and CSF oligomeric NFL concentrations of the study subgroups
| bvFTD | nfvPPA | svPPA | AD | Controls | P value | |
| No | 28 | 23 | 10 | 20 | 20 | |
| M/F | 20/8 | 13/10 | 7/3 | 8/12 | 7/13 | |
| Age, years | 62.6 (59.4–68.2) | 66.3 (63.2–72.1) | 65.2 (57.4–68.7) | 66.9 (63.6–70.1) | 70 (70–70) | 0.0023 |
| Disease duration, years | 6.1 (9.4–3.5) | 4.0 (5.4–2.7) | 5.8 (7.7–1.8) | - * | NA | 0.054 |
| CSF oNfL, pg/mL | 12 554 (18 169–6023) | 22 762 (34 442–12452) | 22 890 (34 447–14525) | 8899 (15 491–5525) | 7150 (10 889–5745) | <0.0001† |
Data are shown as median (IQR).
One-way ANOVA was applied to all study subgroups.
*Samples used for AD diagnostic (early-stage AD).
†bvFTD versus nfvPPA p<0.001, nfvPPA vs AD p<0.01, vs controls p<0.0001, svPPA vs controls p<0.05.
AD, Alzheimer’s disease; ANOVA, analysis of variance; bvFTD, behavioural variant frontotemporal dementia; CSF, cerebrospinal fluid; NA, not applicable; NfL, neurofilament light; nfvPPA, non-fluent variant primary progressive aphasia; oNfL, oligomeric NfL; svPPA, semantic variant primary progessive aphasia.